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IN SILICO LIGAND-BASED 2D PHARMACOPHORE GENERATION FOR H+/K+ 
ATPASE INHIBITORS 
ABSTRACT 
Objectives: At the beginning of the 20
th
 century, Peptic Ulcer became the most prevalent 
disease as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) proved ineffective. Researches 
proved proton pump inhibitors as most successful drugs for the treatment of peptic ulcer. 
Hence, a ligand based pharmacophore was generated on LigandScout based on fifteen 
selected H+/K+ ATPase inhibitors.  
Methods: A pharmacophore model with three Hydrogen bond acceptors, one Hydrogen bond 
donor and one Hydrophobic Domain was developed. The distance between these features was 
estimated on Visual Molecular Dynamics (VMD) software.  
Results: The range between HBA-HBD was found to be 1.89-2.96A. The range between 
HBD-HP was 4.00-5.46A and range between HP-HBA was 1.89-2.96A.  
Conclusion: This research study will thus help in designing new and effective drugs for the 
treatment of peptic ulcer disease. 
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INTRODUCTION 
Gastric H+/K+ ATPase pump is located in the parietal cells [1] and plays a crucial role in the 
formation of ulcers in the stomach. H pylori transmission occurs in 50% of the people 
worldwide [2]. A peptic ulcer is caused by Helicobacter pylori (H. pylori) infection in the 
gastric mucosal lining. This bacterium causes inflammation in the lining of the stomach. In 
response to this, gastrin hormone stimulates the gastric acid production. High levels of gastrin 
cause the enhance release of acid through H+/K+ ATPase pump and lead to the formation of 
the ulcer. High acidic concentration hinders the growth of H pylori. To prevent inhibition of 
growth it releases urease that buffers the environment and breaks down urea into carbon 
dioxide and ammonia. Hence in increased acid production, this bacterium is still able to 
survive [3]. 
H+/K+ ATPase pump consists of 2 subunits; alpha and beta subunits. The main role of alpha 
subunit is for the secretion of gastric acid into the stomach and for hydrolysis of ATP. The 
role of beta subunit is still not understood yet. When the H+/K+-ATPase pump is in an 
inactive state, it is enclosed in a vesicle inside the cytoplasm. But when it is in activated state 
it fits itself into the plasma membrane. It is magnesium dependent and causes exchange of a 
proton against a potassium ion through a membrane. For this process to be efficient, energy is 
required in the form of ATP [1]. 
Researchers have identified H+/K+ ATPase as a therapeutic target for the treatment of Peptic 
ulcer (Sachs et al., 2010). This enzyme is also recognized as a drug target for treatment of 
other various diseases such as dyspepsia, gastroesophageal reflux disease, and Zollinger-
Ellison syndrome. A peptic ulcer can be treated by H+/K+ ATPase pump inhibitors such as 
Omeprazole which is considered as the most effective one for the treatment [4].  
Other proton pump inhibitors include Esomeprazole, Lansoprazole, Rabeprazole, 
Tenatoprazole, and Pantoprazole [5]. As proton pump inhibitors are more effective in the 
treatment, H+/K+ ATPase enzyme is selected as the pharmacologic target. Once the activity 
of H+/K+ ATPase pump is blocked, acid production is reduced in the stomach. H2 blockers 
can also be used to reduce secretion of acid and target on histamine H2-receptor but they 
have severe side effects such as diarrhea, headache, dizziness, rash, and tiredness [6]. 
By blocking the activity of H+/K+ ATPase only the secretion of acid is inhibited but the 
bacterium H. pylori is not eradicated. For the complete treatment of peptic ulcer disease 
  
 
antibiotics such as Metronidazole, Amoxicillin and Clarithromycin with one proton pump 
inhibitor are taken orally [7].  
Effective and new proton pump inhibitors could possibly be discovered via pharmacophore 
modelling. In this approach, essential binding features of a specified drug are identified and 
the pharmacophore model is developed on the basis of analysis of the enzyme inhibitors. [8]. 
In 1909 Paul Ehrlich coined the concept of pharmacophore [9]. The features that are 
described by the pharmacophore model are significant binding features that bind to the target 
of interest. Recently novel inhibitors have been identified for various diseases by 
pharmacophoric modeling. In 2013, Wang et al. [10] generated a pharmacophore based on 
H1 receptor antagonists. Recently a pharmacophore was designed by Valasani for the 
identification of novel cyclophilin d inhibitors [11]. These researchers proved to be 
successful hence till now pharmacophore methodology is still being used to identify novel 
drugs for the treatment of various diseases. 
The essential features of the drug are identified using computational methods.  Both 
structures based and ligand based pharmacophores can be generated by using this software. 
The possible features that are highlighted are Hydrogen bond acceptor, Hydrogen bond 
donor, Aromatic ring, Hydrophobic interactions, Negative and positive ionizable areas [12]. 
These are basically the ligand features that bind to the specific target and initiate a biological 
activity.  
The main goal of this software is to generate a pharmacophore which is a very important step 
in the discovery of a novel drug. The pharmacophore is then validated by computational 
tools. The pharmacophore can also be validated by molecular docking in which the ligand is 
docked against its specific target. The main aim of this study is to generate a ligand based 
pharmacophore on the basis of proton pump inhibitors that can be helpful in discovering a 
new drug for the treatment of peptic ulcer disease.  
Using computational tools is a novel approach for generating pharmacophores. The software 
used is fast and accurate with advanced 3D graphics. Previously pharmacophores were 
generated manually. This approach was time-consuming as it is a lengthy process, therefore, 
new computational tools were developed for drug designing to accelerate the drug 
development process by saving time, financial, human and technical resources. This software 
aligns ligands of different inhibitors and detects an appropriate pharmacophore model [13].  
The detected features are represented by this software. In this study, a pharmacophore will be 
generated which can further be used for discovering a new and effective drug for the 
treatment of peptic ulcer disease by using modern computational techniques.  
MATERIALS AND METHODS 
Ligand Identification 
The extensive survey identified H+/K+ ATPase as a potential target for generating a 
pharmacophore for treating peptic ulcer disease. 
Structure Retrieval  
The drugs that are FDA approved were collected from PubChem Compound category at 
National Center for Biotechnology Information (NCBI) website. PubChem is a large database 
that contains validated information of chemical compounds [14]. The drugs with the least 
IC50 values were selected. IC50 value is the concentration of the drug that is required to 
inhibit any biological target by 50%. The drugs are saved in 2D display and SDF format. SDF 
is one of the file formats of chemical compounds and stands for a structured data file. It 
represents multiple chemical structures and contains associated data.  
Pharmacophore Generation 
Pharmacophore was generated on LigandScout 3.1. The ligandscout software is available on 
(www.inteligand.com). This software aligns all the common features of the training set and 
  
 
creates a 2D pharmacophore. This software is widely used for designing pharmacophore as it 
is fast software and provides high-performance alignment. Each drug was imported onto the 
software. The energy was minimized of the ligand. Pharmacophore model was created by 
clicking the “create pharmacophore” icon in the menu bar. The same was done for each drug. 
Three common features were selected manually. The training set was imported to 
LigandScout altogether. The common features were aligned and commonly featured 
pharmacophore was generated. 
Feature Selection 
The features of the ligand include Hydrogen bond acceptor and Hydrogen bond donor, 
Aromatic ring, hydrophobic interactions, Negative and positive ionizable areas. The features 
that were common in all the drugs were selected. Minimum 3 features are selected for the 
formation of a distance triangle.  
Structure Conversion and compatibility 
The software Visual Molecular Dynamics (VMD) does not support sdf format. Therefore it is 
necessary to convert the drugs into PDB format. The software used for conversion is open 
Babel (http://openbabel.org/wiki/Main_Page). It is free software used to convert more than 
110 file formats. 
Pharmacophore Distance Triangle Calculation 
By using the software Visual Molecular Dynamics (VMD), all possible distance triangles 
were made between the three common features. Minimum - Maximum range of the features 
was observed. VMD is a computational tool which is free of cost for analyzing molecular 
dynamics models. This software was released in 2012 and is a successful tool for displaying 
and processing volumetric data. 
RESULTS 
Retrieved Data set 
Table 1 shows the data that was collected from PubChem. These drugs were selected as they 
had the least IC50 value and they are effective in inhibiting H+/K+ ATPase pump. 
Table 1: Data Set and their IC50 values 
Compound IC50 Value/ μM 
Benzimidazole 0.25 
Bafilomyclin Al 0.44 
Dexlansoprazole 8.0 
Esomeprazole 8.0 
Imidazopyridine 2.3 
Lansoprazole 0.4 
Omeprazole 0.03 
Protonix TN 6.8 
Pantoprazole 1.4 
PF 3716556 6.02 
Rabeprazole 1.7 
Revaprazan 0.039 
Tenatoprazole 3.0 
Timoprazole 1.9 
Zegerid 0.03 
  
 
2D and 3D Pharmacophore Models of each Drug  
The Figures 1-15 represent the 2D and 3D pharmacophores of each drug. Fig 16 shows a 
commonly featured pharmacophore of all compounds. Figures 1-15 shows that each 
compound consists of hydrophobic domain (yellow spheres), Hydrogen bond acceptor (red 
spheres) and Hydrogen bond donor (green spheres). 
  
Fig. 1: Pharmacophore model of bafilomycin A1 (a) 2D model (b) 3D model 
  
Fig. 2: Pharmacophore model of Benzimidazole (a) 2D model (b) 3D model 
  
  
 
Fig. 3: Pharmacophore model of Dexlansoprazole (a) 2D model (b) 3D model 
  
Fig. 4: Pharmacophore model of Esomeprazole (a) 2D model (b) 3D model 
  
Fig. 5: Pharmacophore model of imidazopyridine (a) 2D model (b) 3D model 
  
  
 
Fig. 6: Pharmacophore model of Lansoprazole (a) 2D model (b) 3D model 
  
Fig. 7: Pharmacophore model of Omeprazole (a) 2D model (b) 3D model 
  
Fig. 8: Pharmacophore model of Pantoprazole (a) 2D model (b) 3D model 
  
  
 
Fig. 9: Pharmacophore model of PF 3716556 (a) 2D model (b) 3D model 
  
Fig. 10: Pharmacophore model of Protonix (TN) (a) 2D model (b) 3D model 
   
Fig. 11: Pharmacophore model of Rabeprazole (a) 2D model (b) 3D model 
  
Fig. 12: Pharmacophore model of Revaprazan (a) 2D model (b) 3D model 
  
 
  
Fig. 13: Pharmacophore model of Tenatoprazole (a) 2D model (b) 3D model 
  
Fig. 14: Pharmacophore model of Timoprazole (a) 2D model (b) 3D model 
  
Fig. 15: Pharmacophore model of Zegerid (a) 2D model (b) 3D model 
Fig. 1 shows the 2D and 3D structure of bafilomycin A1. It consists of one HBA, one HBD, 
and three hydrophobic domains.  Fig. 2 shows the 2D and 3D structure of benzimidazole. It 
consists of eight HBA's, four HBDs and ten hydrophobic domains.  Fig. 3 shows the 2D and 
  
 
3D structure of dexlansoprazole. It has seven HBA’s, one HBD and seven hydrophobic 
domains. Fig. 4 shows the structure of Esomeprazole. It has sixteen HBA’s, four HBDs and 
ten hydrophobic domains. Fig. 5 shows the structure of Imidazopyridine. It has two HBA’s, 
one HBD and three hydrophobic domains. Fig. 6 shows the structure of Lansoprazole. It has 
seven HBA’s, one HBD and seven hydrophobic domains. Fig. 7 shows the structure of 
omeprazole. It has five HBA’s, six HBDs and one hydrophobic domain. Fig. 8 shows the 
structure of Protonix TN. It has twenty-one HBA’s, three HBDs and ten hydrophobic 
domains. Fig. 9 shows the structure of pantoprazole. It has eight HBA’s, one HBD and six 
hydrophobic domains. Fig. 10 shows the structure of PF 3716556. It has four HBA’s, two 
HBDs and six hydrophobic domains. Fig. 11 shows the structure of rabeprazole. It has five 
HBA’s, one HBD and six hydrophobic domains. Fig. 12 shows the structure of rev apr azan. 
It has three HBA's, one HBD and ten hydrophobic domains. Fig. 13 shows the structure of 
tenatoprazole. It has six HBA’s, one HBDs and six hydrophobic domains. Fig. 14 shows the 
structure of timoprazole. It has three HBA’s, one HBD and five hydrophobic domains. Fig. 
15 shows the structure of Zegerid. It has ten HBA’s, three HBDs and six hydrophobic 
domains. Fig 16 shows a commonly featured pharmacophore of all compounds.  All 
compounds were aligned at high performance using LigandScout. 
 
Fig. 16: Pharmacophore model of all compounds 
Pharmacophoric Features  
The features that were common in the drugs were Hydrophobic Domain, Hydrogen bond 
acceptor and Hydrogen bond donor. The pharmacophore of all compounds contained one 
hydrophobic domain, three Hydrogen Bond Acceptors, and one Hydrogen bond donor. The 
pharmacophoric features of the ligands are listed in Table 2. The distance triangles within a 
range were selected for each drug as shown in Table 4 Minimum to the maximum range was 
set which had the least difference. 
 
 
 
 
 
  
 
 
Table 2: Pharmacophoric features of each drug 
 
Compound 
 
HBA 
 
HBD 
 
HP/Ar 
 
Positive 
ionizable 
 
Negative 
ionizable 
Benzimidazole 1 1 3 0 0 
Bafilomyclin Al 8 4 10 0 0 
Dexlansoprazole 7 1 7 0 0 
Esomeprazole 16 4 10 0 3 
Imidazopyridine 2 1 3 0 0 
Lansoprazole 7 1 7 0 0 
Omeprazole 5 6 1 0 0 
Protonix TN 21 3 10 2 2 
Pantoprazole 8 1 6 0 0 
PF 3716556 4 2 6 0 0 
Rabeprazole 5 1 6 0 0 
Revaprazan 3 1 10 0 0 
Tenatoprazole 6 1 6 0 0 
Timoprazole 3 1 5 0 0 
Zegerid 10 3 6 2 2 
 
Distance triangles of Pharmacophoric Features 
Table 3 shows the distances calculated by the software Visual Molecular Dynamics. The 
distances shown are the distances between the common features. Table 4 shows the distance 
triangles that were within range. 
Table 3: Distance triangles of all compounds 
Compound HBA-HBD HBD-HP HP-HBA 
Bafilomycin A1 2.33 4.59 3.81 
 
4.15 8.14 8.89 
 
6.68 8.14 4.9 
 
6.26 8.14 6.37 
 
5.97 4.91 2.9 
  
 
 
4.17 6.18 5.4 
 
4.84 6.18 6.15 
 
6.85 5.31 4.04 
 
4.21 4.04 6.08 
 
4.02 2.46 5.41 
Benzimidazole 2.22 4.1 3.74 
 
2.22 5.72 4.15 
 
2.22 2.53 3.61 
 
2.22 1.37 2.28 
 
2.22 2.18 1.37 
 
2.22 3.51 2.52 
Dexlansoprazole 2.22 5.89 5.48 
 
2.22 4.09 3.73 
 
2.96 3.51 6.03 
 
6.05 3.51 7.42 
 
8.07 3.51 10.21 
 
9.98 5.23 6.54 
Esomeprazole 2.93 6.18 7.27 
 
2.73 5.91 6.62 
 
1.89 4.41 3.35 
Imidazopyridine 2.22 2.54 3.6 
 
2.22 3.69 4.08 
 
2.22 4 3.58 
 
3.48 2.54 2.87 
 
3.48 3.69 2.44 
 
3.48 2.54 2.87 
 
3.48 1.37 2.41 
 
3.48 1.37 3.44 
Lansoprazole 2.22 4.09 3.73 
 
2.96 4.09 6.89 
 
8.07 3.51 10.21 
 
6.05 7.18 2.76 
Omeprazole 2.22 3.72 4.16 
 
4.97 3.51 4.97 
 
2.95 5.91 3.57 
 
6.03 3.51 7.36 
  
 
 
8.1 3.51 10.23 
 
2.22 4.09 3.73 
Pantoprazole 4.96 3.51 3.64 
 
2.92 4.75 3.36 
 
2.92 5.24 2.75 
 
5.42 5.24 3.69 
 
6.53 2.53 8.17 
PF3716556 3.74 4.27 3.27 
 
2.96 4.23 3.56 
 
5.7 5.8 6.08 
 
6.4 7.55 7.03 
 
8.09 5.29 7.77 
 
6.4 5.29 3.56 
 
5.7 5.8 6.08 
Protonix TN 2.7 5.46 3.71 
 
4.84 8.67 7.23 
 
3.67 8.29 5.65 
 
7.14 8.29 2.36 
 
9.63 10.52 2.44 
Rabeprazole 2.22 3.72 4.15 
 
2.94 3.51 6.03 
 
2.22 4.09 3.73 
 
7.18 3.72 8.25 
 
9.04 4.09 7.23 
 
5.35 3.51 6.2 
Revaprazan 2.39 3.55 2.73 
 
2.3 5.45 3.78 
 
2.3 4.72 3.07 
 
4.63 5.45 2.86 
 
5.55 3.6 7.97 
    
Tenatoprazole 2.23 3.69 4.07 
 
2.92 5.67 4.83 
 
6.09 5.67 2.42 
 
2.23 3.99 3.57 
 
7.77 3.69 9.92 
 
5.38 5.67 8.4 
Timoprazole 2.22 3.72 4.15 
  
 
 
2.22 4.09 3.74 
 
2.94 4.38 3.13 
 
4.14 2.18 4.28 
 
2.22 3.51 2.51 
Zegerid 2.23 4.09 3.74 
 
3.85 4.61 5.23 
 
4.96 3.76 7.69 
 
6.57 4.92 2.38 
 
2.23 3.72 4.17 
 
Table 4: Distance triangles within range 
Compound HBA-HBD HBD-HP HP-HBA 
Bafilomycin A1 2.33 4.59 3.81 
Benzimidazole 2.22 4.10 3.74 
Dexlansoprazole 2.22 4.09 3.73 
Esomeprazole 1.89 4.41 3.35 
Imidazopyridine 2.22 4.00 3.58 
Lansoprazole 2.22 4.09 3.73 
Omeprazole 2.22 4.09 3.73 
Pantoprazole 2.92 4.75 3.36 
PF3716556 2.96 4.23 3.56 
Protonix TN 2.70 5.46 3.71 
Rabeprazole 2.22 4.09 3.73 
Revaprazan 2.30 4.72 3.07 
Tenatoprazole 2.23 3.99 3.57 
Timoprazole 2.22 4.09 3.74 
Zegerid 2.23 4.09 3.74 
Fig. 17 shows the ranges between the common features. Minimum to the maximum range has 
been calculated between HBA-HBD, HBD-HP, and HP-HBA. The distance between HBA-
HBD is 1.89-2.96A. The range between HBD-HP is 4.00-5.46A and range between HP-HBA 
is 3.07-3.81A. 
 
Fig 17: Distance ranges of common Pharmacophoric Features. Red sphere represents 
HBA, green sphere represents HBD and yellow sphere represents hydrophobic domain 
  
 
DISCUSSION 
Traditional methods of designing a drug are not appreciated because of time-consuming and 
costly processes. Nowadays computer aided drug designing is a highly adopted method for 
drug designing as it replaces the drawbacks of conventional methods. A peptic ulcer is among 
the most prevalent diseases since the 20
th
 century. Numbers of FDA approved drugs are 
available in the market to treat peptic ulcer. All the drugs belong to different classes are 
competent and effective to cure the disease.  No pharmacophore model has been developed 
for these drugs against the target H+/K+ ATPase. 
Fifteen drugs were selected with the least IC50 values for the generation of pharmacophore 
model. The model was designed on the latest version of LigandScout that is LigandScout 
3.11. For constructing a pharmacophore model, identification of ligand features is necessary. 
These features are the important binding features that bind to the target and initiate a 
biological response. The ligand features of the drugs were Hydrogen bond acceptor, 
Hydrogen bond donor, Aromatic ring, Hydrophobic interactions, Negative and positive 
ionizable areas. Hydrogen bond acceptor, Hydrogen bond donor, hydrophobic domain were 
selected as pharmacophoric features. Minimum three features are necessary to form a 
distance triangle. 
The merged pharmacophore model generated had three Hydrogen bond acceptors, one 
Hydrogen bond donor and one hydrophobic domain. These chemical features have high 
affinity towards the target hence are the key features of an effective proton pump inhibitor.  
The distance between these features was calculated on VMD software. This is competent 
software and is used to calculate the range of the common features. The range for the 
pharmacophore was also observed (shown in table 4.4). The distance range observed between 
HBA-HBD was 1.89-2.96A°. The lower limit (1.89A°) of distance range between HBA-HBD 
was followed by Esomeprazole whereas upper limit (2.96A°) was observed in Lansoprazole. 
All other distances lie in between the range. The distance range between HBD-HP was 4.00-
5.46A°. The lower limit (4.00A°) was observed in Imidazopyridine and upper limit (5.46A°) 
was observed in Protonix TN. The distance range between HP-HBA was 3.07-3.81A°. The 
lower limit (3.07A°) was observed in Revaprazan and upper limit (3.81A°) was observed in 
Bafilomycin A1. Different scientists such as Wang [10] generated a pharmacophore based on 
H1 receptor antagonists. Recently a pharmacophore was designed by Valasani et al. [11] for 
the identification of novel cyclophilin d inhibitors [11]. 
The difference between the ranges is approximately 1 Angstrom. This is the ideal difference 
between the ranges in a distance triangle according to different research articles. Hence these 
ranges are accepted. On the basis of these ranges and features, a further refinement can be 
done to improve the efficacy of the drugs. Pharmacophore generation is the initial step for 
discovering a novel proton pump inhibitor. These inhibitors are effectively used in treating 
peptic ulcer disease. 
CONCLUSION 
This study outlines pharmacophore model and the distance range between the common the 
features of H+/K+ ATPase inhibitors. The model that is designed has three Hydrogen bond 
acceptors, one Hydrogen bond donor and one hydrophobic domain. The distance range 
between HBA-HBD is 1.89-2.96A. The range between HBD-HP is 4.00-5.46A and range 
between HP-HBA is 1.89-2.96A. This will be helpful in designing new and effective drugs 
for the treatment of peptic ulcer disease. 
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